Jump to Main Content

FDA Alerts

FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma

The Food and Drug Administration granted accelerated approval to zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Citations